Clindamycin 2% | Tretinoin 0.025% | Niacinamide 3%
Clindamycin 2% | Tretinoin 0.025% | Niacinamide 3% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This compounded topical gel combines clindamycin 2%, tretinoin 0.025%, and niacinamide 3% for the prescriber-directed management of acne vulgaris. Clindamycin at 2% provides enhanced antibacterial activity against Cutibacterium acnes; tretinoin normalizes follicular epithelial differentiation and reduces comedone formation; and niacinamide provides complementary anti-inflammatory activity, barrier support, and sebum modulation. Together, these three agents target the major pathophysiologic axes of acne—bacterial colonization, abnormal keratinization, and inflammation. Genesis Compounding prepares this as a prescription-only 503A compounded preparation for patient-specific use.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Clindamycin 2% | Lincosamide antibiotic that inhibits <em>C. acnes</em> growth by blocking 50S ribosomal protein synthesis, reducing bacterial-driven inflammation in the pilosebaceous unit at a concentration above standard commercial preparations. |
| Tretinoin 0.025% | First-generation retinoid (all-trans retinoic acid) that binds retinoic acid receptors (RARs) to normalize follicular epithelial differentiation, accelerate corneocyte shedding, and suppress microcomedone formation—the primary precursor of all acne lesions. |
| Niacinamide 3% | Topical vitamin B3 derivative that modulates NF-κB-mediated inflammatory signaling in keratinocytes, enhances skin barrier ceramide synthesis, reduces sebum production, and complements both antibiotic and retinoid activity through its anti-inflammatory and barrier-restoring properties. |
Route: Topical application to acne-affected skin areas as directed by the prescriber.
- Cleanse and gently dry skin before application.
- Apply a thin, even layer to the affected area(s) once daily in the evening.
- Avoid eye area, lips, and mucous membranes.
- Evening/nighttime use is preferred due to tretinoin's photolability and photosensitizing effects.
- Use broad-spectrum SPF 30+ sunscreen daily while using this medication.
Prescriber determines the specific dosing schedule, duration, and body areas to treat. General guidance:
- Apply once daily (evening) to acne-affected areas.
- For sensitive skin, begin with every-other-night application, increasing frequency as tolerance develops.
- Allow 8–12 weeks before full clinical assessment; acne treatment requires consistent long-term use.
- Niacinamide inclusion may reduce the retinoid-associated erythema and dryness that often limit adherence.
- Clindamycin (2%): Bacteriostatic; inhibits 50S ribosomal subunit in C. acnes, reducing colonization and lipase-mediated conversion of triglycerides to inflammatory free fatty acids in the follicle. Higher concentration may address populations with reduced clindamycin susceptibility.
- Tretinoin (0.025%): RAR-α, -β, -γ agonist; receptor-ligand complexes activate retinoid hormone response elements in keratinocyte nuclei, normalizing follicular cornification, loosening corneocyte cohesiveness, facilitating comedone expulsion, and blocking microcomedone formation. Also upregulates procollagen I and III via AP-1 blockade.
- Niacinamide: Inhibits PARP-1 and NF-κB activity in keratinocytes, reducing transcription of IL-1α, IL-6, TNF-α, and CXCL8; stimulates ceramide, cholesterol, and sphingomyelin synthesis to restore permeability barrier; modestly suppresses sebocyte activity and reduces melanosome transfer to keratinocytes.
Used for mild to moderate acne vulgaris—particularly mixed inflammatory and comedonal acne requiring antibacterial, retinoid, and complementary anti-inflammatory coverage. The addition of niacinamide may improve tolerability of the retinoid component and provide post-inflammatory hyperpigmentation benefit, which is especially relevant in patients with higher Fitzpatrick skin types.
Prescriber monitoring:
- Confirm absence of pregnancy before initiating tretinoin (Category X).
- Monitor for retinoid-associated irritation (erythema, dryness, peeling); reduce frequency if severe.
- Monitor for antibiotic resistance development with prolonged clindamycin use.
- Advise daily broad-spectrum sunscreen use and sun avoidance.
Contraindications:
- Pregnancy (tretinoin; Category X)
- Hypersensitivity to clindamycin, lincomycin, tretinoin, or niacinamide
- History of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (clindamycin)
Warnings & Precautions:
- Tretinoin teratogenicity: advise pregnancy avoidance; confirm contraceptive use if applicable.
- Photosensitivity: use sunscreen daily; avoid prolonged sun exposure on treated skin.
- Retinoid irritation: dryness, peeling, and erythema are expected in initial weeks; reduce frequency if severe, do not discontinue without prescriber guidance.
- Antibiotic-associated colitis with topical clindamycin: rare, but persistent diarrhea warrants evaluation.
Drug Interactions:
- Avoid concurrent strong topical peeling agents (high-concentration AHAs, BHAs, benzoyl peroxide, sulfur) on same areas—additive irritation with tretinoin.
- Erythromycin is antagonistic to clindamycin antibacterial activity; avoid concurrent use.
Common Side Effects: Skin dryness, erythema, peeling, burning sensation on application (tretinoin-related—most common in first 4 weeks); photosensitivity; rare: antibiotic-associated diarrhea (clindamycin).
Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and heat—tretinoin degrades under UV exposure. Do not freeze. Keep tightly capped. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
What does each ingredient do in this acne formula?
Clindamycin (2%) kills C. acnes bacteria that drive inflammation. Tretinoin (0.025%) normalizes follicular shedding and prevents the microcomedones that become all acne lesions. Niacinamide (3%) reduces inflammation, supports skin barrier repair, and may reduce the irritation that tretinoin causes—as well as helping fade post-acne dark spots.
Why is clindamycin at 2% rather than the usual 1%?
This formulation was compounded to the prescriber's specification at 2% for this patient's clinical needs. Higher concentrations may be chosen for cases with greater bacterial load or in patients who have not responded optimally to standard concentrations.
Can I use this medication if I am pregnant?
No. Tretinoin is classified as FDA Pregnancy Category X and is contraindicated during pregnancy. Inform your prescriber immediately if pregnancy occurs during treatment. Reliable contraception is required while using this medication.
Is this product FDA-approved?
No. This is a 503A compounded topical preparation from Genesis Compounding, prepared for a specific patient on a prescriber's order. An FDA-approved combination of clindamycin and tretinoin exists commercially, but this compounded formulation at these exact concentrations and with niacinamide is not an FDA-approved product.
Why should I apply this at night?
Tretinoin is degraded by ultraviolet light and increases the skin's sensitivity to UV radiation. Evening application minimizes photodegradation of the active ingredient and reduces the risk of photosensitivity reactions. Always apply broad-spectrum SPF 30+ sunscreen in the morning.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.